FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306644966> ?p ?o ?g. }

• W4306644966 abstract "Abstract Background Non-invasive biomarkers of immune checkpoint inhibitor-associated acute tubulointerstitial nephritis (ICI-nephritis) are urgently needed. Because ICIs block immune checkpoint pathways that include cytotoxic T lymphocyte antigen 4 (CTLA4), we hypothesized that biomarkers of immune dysregulation previously defined in patients with congenital CTLA4 deficiency, including elevated soluble interleukin-2 receptor alpha (sIL-2R) and flow cytometric cell-based markers of B and T cell dysregulation in peripheral blood may aide the diagnosis of ICI-nephritis. Methods A retrospective cohort of patients diagnosed with ICI-nephritis was compared to three prospectively enrolled control cohorts: ICI-treated controls without immune related adverse events, patients not on ICIs with hemodynamic acute kidney injury (hemodynamic AKI), and patients not on ICIs with biopsy proven acute interstitial nephritis from other causes (non-ICI-nephritis). sIL-2R level and flow cytometric parameters were compared between groups using Wilcoxon rank sum test or Kruskal-Wallis test. Receiver operating characteristic curves were generated to define the accuracy of sIL-2R and flow cytometric biomarkers in diagnosing ICI-nephritis. The downstream impact of T cell activation in the affected kidney was investigated using archived biopsy samples to evaluate the gene expression of IL2RA , IL-2 signaling, and T cell receptor signaling in patients with ICI-nephritis compared to other causes of drug-induced nephritis, acute tubular injury, and histologically normal controls. Results sIL-2R level in peripheral blood was significantly higher in patients with ICI-nephritis (N=24) (median 2.5-fold upper limit of normal [ULN], IQR 1.9-3.3), compared to ICI-treated controls (N=10) (median 0.8-fold ULN, IQR 0.5-0.9, P <0.001) and hemodynamic AKI controls (N=6) (median 0.9-fold-ULN, IQR 0.7-1.1, P =0.008). A sIL-2R cut-off point of 1.75-fold ULN was highly diagnostic of ICI-nephritis (AUC >96%) when compared to either ICI-treated or hemodynamic AKI controls. By peripheral blood flow cytometry analysis, lower absolute CD8+ T cells, CD45RA+CD8+ T cells, memory CD27+ B cells, and expansion of plasmablasts were prominent features of ICI-nephritis compared to ICI-treated controls. Gene expression for IL2RA , IL-2 signaling, and T cell receptor signaling in the kidney tissue with ICI-nephritis were significantly higher compared to controls. Conclusion Elevated sIL-2R level and flow cytometric markers of both B and T cell dysregulation may aid the diagnosis of ICI-nephritis. Key Messages What is already known on this topic There are no non-invasive biomarkers of immune checkpoint inhibitor-associated nephritis (ICI-nephritis); kidney biopsy, the gold standard for diagnosing ICI-nephritis, can be challenging or even contraindicated given its periprocedural risk. There are mechanistic and clinicopathologic similarities between immune-related adverse events and congenital CTLA4 deficiency. What this study adds Established biomarkers of congenital CTLA4 deficiency, including elevated serum sIL-2R level and flow cytometric markers of both B and T cell dysregulation, are promising biomarkers for diagnosis of ICI-nephritis. These markers are not altered in patients treated with immune checkpoint inhibitors who are not experiencing immune-related adverse events. How this study might affect research, practice or policy Prospective study with longitudinal sIL-2R and peripheral flow cytometry measurements are needed to validate the result and may limit the need for invasive diagnosis of ICI-nephritis." @default.
• W4306644966 created "2022-10-18" @default.
• W4306644966 creator A5006587230 @default.
• W4306644966 creator A5008479799 @default.
• W4306644966 creator A5010083701 @default.
• W4306644966 creator A5011634251 @default.
• W4306644966 creator A5013097108 @default.
• W4306644966 creator A5019248592 @default.
• W4306644966 creator A5021446947 @default.
• W4306644966 creator A5035343389 @default.
• W4306644966 creator A5038605279 @default.
• W4306644966 creator A5041018489 @default.
• W4306644966 creator A5043793593 @default.
• W4306644966 creator A5046220535 @default.
• W4306644966 creator A5048669465 @default.
• W4306644966 creator A5071570508 @default.
• W4306644966 creator A5076630521 @default.
• W4306644966 creator A5083608773 @default.
• W4306644966 creator A5084293710 @default.
• W4306644966 creator A5084355410 @default.
• W4306644966 date "2022-10-17" @default.
• W4306644966 modified "2023-09-26" @default.
• W4306644966 title "Soluble and cell-based markers of immune checkpoint inhibitor associated nephritis" @default.
• W4306644966 cites W1486621660 @default.
• W4306644966 cites W1512843295 @default.
• W4306644966 cites W1574766328 @default.
• W4306644966 cites W1965557074 @default.
• W4306644966 cites W1967067685 @default.
• W4306644966 cites W1977119466 @default.
• W4306644966 cites W2012467309 @default.
• W4306644966 cites W2014198428 @default.
• W4306644966 cites W2017052406 @default.
• W4306644966 cites W2062738885 @default.
• W4306644966 cites W2075660270 @default.
• W4306644966 cites W2081255498 @default.
• W4306644966 cites W2109318711 @default.
• W4306644966 cites W2112601576 @default.
• W4306644966 cites W2137345140 @default.
• W4306644966 cites W2147800731 @default.
• W4306644966 cites W2158384363 @default.
• W4306644966 cites W2158515517 @default.
• W4306644966 cites W2413514895 @default.
• W4306644966 cites W2547133566 @default.
• W4306644966 cites W2594468280 @default.
• W4306644966 cites W2624328215 @default.
• W4306644966 cites W2778206556 @default.
• W4306644966 cites W2781484625 @default.
• W4306644966 cites W2810821243 @default.
• W4306644966 cites W2897483443 @default.
• W4306644966 cites W2900360032 @default.
• W4306644966 cites W2942204681 @default.
• W4306644966 cites W2945207519 @default.
• W4306644966 cites W2950056455 @default.
• W4306644966 cites W2969665548 @default.
• W4306644966 cites W2984413960 @default.
• W4306644966 cites W2997561837 @default.
• W4306644966 cites W2999959360 @default.
• W4306644966 cites W3005947910 @default.
• W4306644966 cites W3010374810 @default.
• W4306644966 cites W3023745224 @default.
• W4306644966 cites W3026304753 @default.
• W4306644966 cites W3037088183 @default.
• W4306644966 cites W3044041426 @default.
• W4306644966 cites W3087453884 @default.
• W4306644966 cites W3127826897 @default.
• W4306644966 cites W3128640839 @default.
• W4306644966 cites W3134655285 @default.
• W4306644966 cites W3174077356 @default.
• W4306644966 cites W3202872245 @default.
• W4306644966 cites W4220804543 @default.
• W4306644966 cites W4293851059 @default.
• W4306644966 doi "https://doi.org/10.1101/2022.10.13.22280966" @default.
• W4306644966 hasPublicationYear "2022" @default.
• W4306644966 type Work @default.
• W4306644966 citedByCount "0" @default.
• W4306644966 crossrefType "posted-content" @default.
• W4306644966 hasAuthorship W4306644966A5006587230 @default.
• W4306644966 hasAuthorship W4306644966A5008479799 @default.
• W4306644966 hasAuthorship W4306644966A5010083701 @default.
• W4306644966 hasAuthorship W4306644966A5011634251 @default.
• W4306644966 hasAuthorship W4306644966A5013097108 @default.
• W4306644966 hasAuthorship W4306644966A5019248592 @default.
• W4306644966 hasAuthorship W4306644966A5021446947 @default.
• W4306644966 hasAuthorship W4306644966A5035343389 @default.
• W4306644966 hasAuthorship W4306644966A5038605279 @default.
• W4306644966 hasAuthorship W4306644966A5041018489 @default.
• W4306644966 hasAuthorship W4306644966A5043793593 @default.
• W4306644966 hasAuthorship W4306644966A5046220535 @default.
• W4306644966 hasAuthorship W4306644966A5048669465 @default.
• W4306644966 hasAuthorship W4306644966A5071570508 @default.
• W4306644966 hasAuthorship W4306644966A5076630521 @default.
• W4306644966 hasAuthorship W4306644966A5083608773 @default.
• W4306644966 hasAuthorship W4306644966A5084293710 @default.
• W4306644966 hasAuthorship W4306644966A5084355410 @default.
• W4306644966 hasBestOaLocation W43066449661 @default.
• W4306644966 hasConcept C126322002 @default.
• W4306644966 hasConcept C203014093 @default.
• W4306644966 hasConcept C2777058396 @default.
• W4306644966 hasConcept C2780472472 @default.
• W4306644966 hasConcept C71924100 @default.

• next